CIA

The Culinary Institute of America Announces New Trustees

Retrieved on: 
Thursday, November 9, 2023
The Culinary Institute of America, Principal, Adur Burzen-Mihr, Faculty, Culinary Institute, Trustee, Food, Heart, Corporation, SingleThread, Growth, Curriculum, Foodservice, Michelin, CIA, Management, Crocinis, Operation

Hyde Park, New York--(Newsfile Corp. - November 9, 2023) - The Culinary Institute of America (CIA) named three new trustees to its board during its October annual meeting: Arash Azarbarzin, Kyle Connaughton, and Adam Crocini.

Key Points: 
  • Hyde Park, New York--(Newsfile Corp. - November 9, 2023) - The Culinary Institute of America (CIA) named three new trustees to its board during its October annual meeting: Arash Azarbarzin, Kyle Connaughton, and Adam Crocini.
  • Kyle Connaughton is a celebrated chef, culinary educator, and owner of the three-Michelin-starred SingleThread Farm-Restaurant-Inn in Healdsburg, CA.
  • Most recently, he helped design the CIA's new Master's in Culinary Arts program and serves as one of the program's culinary mentors.
  • "Their leadership, experience, and forward-thinking mindsets will help ensure the CIA continues to be the gold standard in culinary education."

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Research and development, American College, IND, MGD, PD, Public expenditure, Investigational New Drug, G&A, Inflammation, Treatment of lung cancer, MYC, R, GSPT1, Neoplasm, CDK2, Drug discovery, DSM-IV codes, Autoimmune disease, American College of Rheumatology, Roche, Cancer, Autoimmunity, Finance, Therapy, Patient, ACR, Administration, CIA, VAV1, Pharmaceutical industry, Vaccine, Cryptocurrency

"This has been a pivotal time for Monte Rosa as we announced both our first clinical data and our first major strategic collaboration,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.

Key Points: 
  • "This has been a pivotal time for Monte Rosa as we announced both our first clinical data and our first major strategic collaboration,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.
  • Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2023 were $28.3 million, compared to $21.3 million for the third quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2023 were $8.7 million compared to $7.0 million for the third quarter of 2022.
  • Net Loss: Net loss for the third quarter of 2023 was $34.9 million, compared to $27.3 million for the third quarter of 2022.

BPGbio Wins 2023 BioTech Breakthrough Award for Therapeutics Platform of The Year

Retrieved on: 
Wednesday, November 8, 2023
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Other Science, Drug discovery, GBM, Harvard Medical School, AstraZeneca, CIA, Netherlands Architecture Institute, Biomarker, Rare, Therapy, Government, Oak Ridge National Laboratory, United States Department of Defense, Supercomputing in India, Carcinoma, Icahn School of Medicine at Mount Sinai, HPC, Organization, SCC, Research, Prostate cancer, Glioblastoma, Liver disease, Multimedia, Medicine, Biology, EB, Neurology, Breast cancer, Pancreatic cancer, Sanofi, AI, ORNL, Mount Sinai, Patient, Epidermolysis bullosa, Sarcopenia, Pharmaceutical industry, Medical device, Neuroscience

View the full release here: https://www.businesswire.com/news/home/20231108370629/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231108370629/en/
    BPGbio named Therapeutics Platform of the Year by Biotech Breakthrough Awards program.
  • The award recognizes BPGbio’s success leveraging their NAi Interrogative Biology Platform to develop late-stage therapeutics and diagnostics for some of the most challenging diseases.
  • “We are honored that BPGbio has won the Therapeutics Platform of the Year from BioTech Breakthrough, a massive achievement for our employees and research partners.
  • BPGbio, our ‘Therapeutics Platform of the Year’ winner, is proving the value of AI in drug discovery for the future of medicine,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards.

VERSES AI Announces Cortical Labs, Biological Computing Company as Second Beta Partner

Retrieved on: 
Tuesday, November 7, 2023
Neuron, Defence Intelligence Agency (India), Central Intelligence Agency, Research, Software, Nature, Partnership, CBOE, Teaching, GPU, Algorithm, Cortex, CIA, 3D printing, Cryptocurrency

VANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSF) ("VERSES'' or the "Company”), a cognitive computing company specializing in biologically inspired distributed intelligence, today announced a partnership with Cortical Labs, a biological hardware startup that is seeking to revolutionize computing by fusing live neurons with silicon chips.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSF) ("VERSES'' or the "Company”), a cognitive computing company specializing in biologically inspired distributed intelligence, today announced a partnership with Cortical Labs, a biological hardware startup that is seeking to revolutionize computing by fusing live neurons with silicon chips.
  • The partnership between VERSES and Cortical Labs marks an alignment of philosophies around the future of computing between software patterned after algorithms found in nature and hardware constructed from brain cells.
  • The VERSES research team will be exploring the development of novel algorithms that leverage Cortical Labs’ synthetic biological intelligence systems with the aim of solving real-world problems.
  • Cortical Labs joins VERSES’ beta partnership program, which intends to feature ten partners across multiple industries and of various sizes and stages interested in using VERSES’ Genius™ platform to deploy smarter and safer intelligent software.

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

Retrieved on: 
Tuesday, November 7, 2023
BCR, Psoriasis, American College, IND, Inflammation, Autoimmunity, Rheumatoid arthritis, HIV disease progression rates, Data, MGD, Poster session, American College of Rheumatology, Multiple sclerosis, Therapy, ACR, Inflammatory bowel disease, CIA, VAV1, Pharmaceutical industry, Vaccine

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data at the American College of Rheumatology (ACR) Convergence Annual Meeting held November 10-15 in San Diego, CA. The data demonstrate that MRT-6160, a novel, highly selective MGD targeting VAV1, attenuated disease progression in a murine collagen-induced arthritis (CIA) model.

Key Points: 
  • The data demonstrate that MRT-6160, a novel, highly selective MGD targeting VAV1, attenuated disease progression in a murine collagen-induced arthritis (CIA) model.
  • In vitro, MRT-6160 induced selective degradation of VAV1, and attenuated TCR- and BCR-mediated activation and function of primary human T- and B-cells.
  • In the CIA model, oral dosing of MRT-6160 elicited rapid VAV1 degradation across multiple tissues in a dose-dependent manner.
  • Over the course of 20 days, MRT-6160 significantly decreased disease progression and endpoint functional scores compared to vehicle and showed a trend towards superior activity compared to an anti-TNF antibody.

FibroGen Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 6, 2023
Sale, JDE, AstraZeneca, LAPC, Pancreatic Cancer Action Network, American Society of Nephrology, CD46, Poster, Society, Bank statement, Chronic kidney disease, Immunotherapy, Growth, ADC, Interest, ASN, Webcast, Abstract, Pamrevlumab, Pancreatic cancer, Oncology, Anemia, CKD, European Society of Gynaecological Oncology, Investment, Patient, CIA, SAN, Shanda, Pharmaceutical industry, Video game, Vaccine, Roxadustat

Total revenue for the third quarter of 2023 was $40.1 million, as compared to $15.7 million for the third quarter of 2022, an increase of 155% year over year.

Key Points: 
  • Total revenue for the third quarter of 2023 was $40.1 million, as compared to $15.7 million for the third quarter of 2022, an increase of 155% year over year.
  • Restructuring charge for the third quarter of 2023 was $12.6 million, or $0.13 impact to net loss per basic and diluted share, resulting from the reduction in U.S. workforce announced in July 2023.
  • The distribution entity jointly owned by AstraZeneca and FibroGen is not consolidated into FibroGen’s financial statements.
  • FibroGen will host a conference call and webcast today, Monday, November 6, 2023, at 5:00 PM Eastern Time to discuss financial results and provide a business update.

10 Things We Learned About OTC Hearing Aids in the Last Year

Retrieved on: 
Monday, November 6, 2023
MA, FDA, Insurance, HP, Kool-Aid, Medicare, Hearing loss, OTC, Person, Jabra, Acquisition, Doctor of Philosophy, Hemp Industries Association, Sony, Advertising, Interview, Internet, Partnership, Pharmacy, Catherine Carr, Hearing, CIA, HIA, Sennheiser, Medical device, Pharmaceutical industry

For those in the hearing care profession and the hearing industry, the wait for the final regulation1 of OTC hearing aids was long, somewhat stressful, and uncertain.

Key Points: 
  • For those in the hearing care profession and the hearing industry, the wait for the final regulation1 of OTC hearing aids was long, somewhat stressful, and uncertain.
  • Now, more than one year after the effective date of the OTC hearing aid rule promulgated by FDA, we have a few observations to share.
  • Examples include claims of restoring natural hearing, treatment of severe hearing loss, and our favorite fallacy – invisible hearing aids that use CIA technology.
  • Powers, PhD, are available for interview on the topics of over-the-counter hearing aids and hearing technology innovation.

Amentum Announces New Client Executive Leader

Retrieved on: 
Monday, October 30, 2023
Technology, Engineering, Homeland Security, Other Energy, Manufacturing, Consulting, Public Policy, Government, Energy, Professional Services, Defense, Environment, Other Defense, State, Local, Security, Australian contribution to the 1991 Gulf War, Intelligence, Assistant, Operation, Distinguished Intelligence Medal, Defence Intelligence Agency (India), Business development, Intelligence Star, Gulf War, Central Intelligence Agency, Organization development, Collection, Investment, Near East, CIA, Management, Science, Psychology, Amentum, United States Army

Amentum, a leading global engineering, advanced intelligence, and systems modernization provider, announced that it welcomed Dave Marlowe as Vice President, Client Executive.

Key Points: 
  • Amentum, a leading global engineering, advanced intelligence, and systems modernization provider, announced that it welcomed Dave Marlowe as Vice President, Client Executive.
  • “Dave brings unparalleled leadership and deep mission insight in the national security space,” said Sean Mullen, Executive Vice President, Business Development.
  • He served most recently as the Deputy Director of CIA for Operations, overseeing the operational work force and global clandestine intelligence collection activity.
  • He is a former U.S. Army enlisted soldier, with service in Iraq during the 1991 Gulf War.

How Suite It Is: Chief Wellness Officer Coming to a Company Near You - Aquila Insight Report

Retrieved on: 
Thursday, November 2, 2023
Delta, Aquila, CWO, Workforce, Aon, Morale, AT&T, EY, CIA, HR, AT, Management, Nursing

Pioneering this change, more companies are now championing the role of the Chief Wellness Officer (CWO), as illuminated by wellbeing leader, Aquila.

Key Points: 
  • Pioneering this change, more companies are now championing the role of the Chief Wellness Officer (CWO), as illuminated by wellbeing leader, Aquila.
  • The CWO initiative, initially aimed at mitigating burnout among healthcare professionals, especially during the pandemic, has expanded across diverse sectors.
  • A CWO's remit involves championing holistic wellness, covering physical, mental, financial, and social health, a niche focus compared to broader HR responsibilities.
  • As a leading force in wellbeing and fitness services, Aquila guides organizations in sculpting effective strategies to promote holistic employee well-being.

The IIA Names Benito Ybarra Executive Vice President of Global Standards, Guidance, and Certifications

Retrieved on: 
Friday, October 27, 2023
Knowledge, Institute of Internal Auditors, Financial audit, Education, CRMA, Strategic planning, International, GGC, CPA, Certification, CCEP, Texas Department of Public Safety, Transport, Organization, Research, Volunteering, CFE, Public sector, IPPF, Ybarra, Global Standards Symposium, PCB, IAP, CGMA, IIA, Texas Department of Transportation, CITP, CIA, CISA, Dell Technologies, Audit, Management

He will work closely with The IIA's International Internal Audit Standards Board (IIASB), the Professional Certifications Board (PCB), and the Global Guidance Council (GGC).

Key Points: 
  • He will work closely with The IIA's International Internal Audit Standards Board (IIASB), the Professional Certifications Board (PCB), and the Global Guidance Council (GGC).
  • "With over 25 years in internal audit leadership globally, Benito brings a wealth of knowledge and expertise to our organization," said IIA President and CEO Anthony Pugliese, CIA, CPA, CGMA, CITP.
  • Further, Ybarra has already made substantial contributions to The IIA in various senior volunteer roles.
  • Additionally, Ybarra actively participated as a member of The IIA International Professional Issues and Guidance Committee and served as President of the IIA North America's Austin, Texas chapter.